SSA
PNT

Schonfeld Strategic Advisors’s POINT Biopharma Global Inc. Common Stock PNT Stock Holding History

Schonfeld Strategic Advisors’s Portfolio PNT Stock Details PNT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-12,192
Closed -$88.9K – 2836
2022
Q4 		$88.9K Sell
12,192
-208
-2% -$1.54K ﹤0.01% 2207
2022
Q3 		$96K Buy
+12,400
New +$105K ﹤0.01% 2569

Other funds holding PNT

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Schonfeld Strategic Advisors's PNT Position: Q1 2023 in Review

Schonfeld Strategic Advisors sold out of POINT Biopharma Global Inc. Common Stock (PNT) in Q1 2023, closing a stake of 12,192 shares — an estimated $88.9K sold.

Schonfeld Strategic Advisors first reported a position in PNT in Q3 2022 and held it in 2 quarters. The position peaked at $96K in Q3 2022. 115 funds tracked by Wall St. Rank hold PNT as of Q1 2023.

  • Schonfeld Strategic Advisors reported no remaining POINT Biopharma Global Inc. Common Stock position as of Q1 2023 after selling out during the quarter.
  • Schonfeld Strategic Advisors sold 12,192 POINT Biopharma Global Inc. Common Stock shares in Q1 2023, an estimated $88.9K.
  • Schonfeld Strategic Advisors first reported a position in POINT Biopharma Global Inc. Common Stock in Q3 2022 and held it in 2 quarters.
  • Schonfeld Strategic Advisors's POINT Biopharma Global Inc. Common Stock position peaked at $96K in Q3 2022.
  • 115 funds tracked by Wall St. Rank held POINT Biopharma Global Inc. Common Stock as of Q1 2023.

Based on Schonfeld Strategic Advisors's 13F filing for Q1 2023, filed 15 May 2023.